NH TherAguix announced the completion of enrollment in NANO-GBM phase Ib/II trial, evaluating the combination of AGuIX® nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed glioblastoma and the publication of the positive Phase Ib outcomes and MRI-based biodistribution data from this trial in the journal Clinical and Translational Radiation Oncology.